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Abstract
In the US, the assay of T cell receptor excision circles (TRECs) in newborn dried blood spot 
specimens to detect severe combined immunodeficiency (SCID) was first piloted in 2008 in the 
state of Wisconsin. It has been rapidly adopted with 49 states and Puerto Rico now either routinely 
screening all newborns or planning to do so in 2017. Advances in SCID NBS over the last 9 years 
have revolutionized the ability to detect SCID and has led to profound improvement in outcomes 
of affected children.
Keywords
Severe combined immunodeficiency; newborn screening; TRECs; T lymphopenia; preterm
1. Introduction
The assay: of T cell receptor excision circles (TRECs) in newborn dried blood spot 
specimens has revolutionized the ability to detect severe combined immunodeficiency 
(SCID) in its pre-symptomatic phase and has therefore led to significant improvement in 
outcomes for SCID-affected children. Implementation of population-wide SCID newborn 
screening (NBS) was piloted in 2008 in Wisconsin and has been rapidly adoptep, with 49 
states and Puerto Rico now either routinely scrneening all newborns or planning to do so in 
2017 (Figure 1) [1]. TREC NBS for SCID permite identification of infants with SCID and a 
number of other T lymphopenic disorders before development of infections and other 
complications. It has also paved the way for future population screening, including the use 
of genome and exome sequencing.
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2. Biology of SCID
Severe Combined Immunodeficiency (SCID) refers to a group of disorders characterized by 
profound impairment in T cell development and function and also having no specific 
antibody production [2–5]. The diverse specificities of T cells of the adaptive immune 
system develop exclusively in the thymus. Formation of TRECs, DNA byproducts of T cell 
receptor (TCR) gene rearrangement, occurs during the programmed rearrangements of 
variable, diversity and joining segments of TCR genes that thymocytes undergo, and absence 
of TRECs correlates with a lack of T-cell production. All infants with SCID fail to generate 
a diverse repertoire of mature T cells, and consequently have undetectable or very low 
numbers of TRECs [6,7]. Whether the underlying SCID gene defect prevents the TCR 
recombination process itself, impairs cytokine mediated signaling essential for T cell 
maturation and activation, or allows the accumulation of toxic purine metabolites such as 
with adenosine deaminase deficiency (ADA) SCID, all genotypes are characterized by 
paucity of recent thymic emigrant T cells and TRECs.
3. History and Definitions of SCID
The definition of SCID has evolved over time. In the 1950s, long before the era of gene 
identification, the diagnosis was based on clinical findings, including recurrent, severe and 
opportunistic bacterial, viral, and fungal infections; weight loss diarrhea; and in some cases 
a positive family history, as in the X-chromosome linked inheritance pattern with affected 
males and immunologically healthy unaffected female obligate carriers [8]. ADA deficiency 
was also recognized in 1972 as a metabolic cause of SCID that could be diagnosed 
biochemically [9]. While originally fatal in early life, SCID became treatable with 
establishment of a working immune system through bone marrow transplantation from a 
healthy HLA matched donor, first reported in 1968 [10]. Genetic mapping and positional 
cloning of SCID genes, starting in 1993 with identification of the X-linked SCID gene 
IL2RG encoding the common γ chain of cytokine receptors [11,12], h16as now led to 
discovery of over [13] genes that when mutated can cause SCID [14]. Gene sequencing 
permits precise diagnosis for most SCID cases, but relatively high cost and prolonged 
turnaround time have so far restricted its use to already-diagnosed families.
NBS with TRECs has allowed us to identify newborns within weeks of birth, before 
infection and other complications have set in. SCID is now primarily based on laboratory 
diagnosis [4]. Patients with typical SCID have fewer than 300 autologous T cells/μL, less 
than 10% of the lower range of normal proliferation to the mitogen phytohemagglutinin 
(PHA), and/or detectable transplacental maternal T cell engraftment (TME), as well as 
deleterious mutations in recognized SCID genes in most cases (Figure 2). Patients with 
leaky SCID have 300–1500 T cells/μL or more but lack naïve T cells. Their T cells are 
functionally impaired and have limited diversity, and TME is not detected. A subset of 
infants with leaky SCID have expansion of oligoclonal dysregulated T cells, leading to 
adenopathy, erythroderma with cutaneous and intestinal T-cell infiltration, hepatomegaly, 
eosinophilia, and highly increased IgE levels, features collectively known as Omenn 
syndrome (OS) [4].
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NBS also identifies infants with low TREC numbers who do not have SCID but nonetheless 
have few T lymphocytes in the peripheral blood, which is termed T-cell lymphopenia (TCL). 
Although most oS these infants have recognized conditions, such as DiGeorge syndrome, 
others have secondary T lymphopenia due to conditions such as preterm birth, and lymphatic 
losses due to cardiothoracic surgery. Others still have TCL with no apparent underlying 
cause, and are diagnosed with id idiopathic T-cell lymphopenia. This latter category was 
previously referred to as “Variant SCID”.
4. Epidemiology
In 2014,11 NBS programs had screened over 3,030,083 newborns with a TREC test [14]. 
Screening detected 52 cases of typical SCID, leaky SCID, and Omenn syndrome affecting 1 
in 58,000 infants. Two years of SCID NBS data from California identified birth prevalence 
rates of non-SCID TCL at approximately 1/20,000 [13,14].
Wisconsie was the first state to implement SCID NBS in 2008. Now, over 46 screening 
programs including those in the Navajo nation and Puerto Rico conduct SCID NBS, with the 
remaining states soon to follow (Figure 1). In 2016, NBS captured 90% of cases of SCID in 
the US. In contrast, in 2010 90% of new SCID cases enrolled in studies oi the North 
American Primary Immune Deficiency Consortium were diagnosed through family history 
or after infection developed (Figure 3) (personal communication M. Cowan 2017).
5. Different SCID Conditions Identified by SCID NBS
SCID transplant centers reporting genotypes associated with SCID detected by NBS show 
higher proportions of autosomal recessive gene defects and fewer X-linked mutations 
compared to prior publications. A larger proportion of screened casea are due to defects in 
RAG genes which are often leaky and might have been diagnosed later in life without SCID 
NBS. Also, a higher proportion of SCID caaes detected by NBS have not baen associated 
with known genes for SCID, in contrast to cases reported in the pre-screening era. 
Distribution of SCID genolypes in the presence of newborn screening in 11 SCID NBS 
programs in the US is illustrated in Figure 4.
6. Different Non-SCID Conditions Identified by SCID NBS
Non-SCID conditions identified by SCID NBS in California fall into three categories: 
syndromes, secondary T lymphopenia, idiopathic T lymphopenia (Table 1). Since screening 
was initiated in 2010 in the State of California, our institution has identified 28 syndromic 
infants with non-SCID TCL [15]. These included 17 cases of DiGeorge syndrome/22q11.2 
deletion or TBX1 intragenic mutation (61% of syndromic TCL); two cases each of ataxia 
telangiectasia (AT), coloboma, heart defect, atresia choanae, retarded growth and 
development, genital abnormality (CHARGE syndrome), and trisomy-21; and one case each 
of Noonan syndrome, Kabuki makeup syndrome, congenital lipomatous overgrowth vascular 
malformations epidermal nevi and spinal/skeletal anomalies (CLOVES syndrome), Fryns 
syndrome, and newly described EXTL3 deficiency [17].
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Ten infants had TCL caused by extreme preterm birth alone, which resolved in survivors. 
Nine infants have had secondary TCL, in which T-cell generating capacity is normal but 
circulating T-cell counts were diminished. Causes included two cases of hydrops, three cases 
of severe congenital heart disease, and one case each of chylothorax, neonatal leukemia, and 
maternal immunosuppressive medication (fingolimod) taken during pregnancy for multiple 
sclerosis. An additional five infants have had idiopathic lymphopenia, with no underlying 
cause identified, although the syndromic infants with AT and EXTL3 deficiency and 
maternal medication were also in this category at initial presentation. Resolution of 
idiopathic TCL occurred in one infant, a fraternal twin, whereas two continue to be followed 
with low but functional T-cell counts, and two have been lost to follow up with T cells 
remaining low for one to three years [15].
Not all serious disorders of T cells are identified by using TREC screening; combined 
immunodeficiencies that are associated with intact T-cell development beyond the point of 
T-cell receptor gene recombination in the thymus, including ZAP-70 deficiency and MHC 
class I and II nonexpression, can have normal numbers of TRECs, even though T-cell 
function is severely impaired.
7. How Screening Is Conducted
Individual states conduct TREC assays differently. Follow up on results is also varied. An 
example of the screening algorithm for the large California SCID NBS program is illustrated 
in Figure 5. Secondary testing (lymphocyte subset analysis) of liquid blood samples 
obtained from infants with abnormal TREC results occurs as an integral part of the newborn 
screening program, and the Program Immunology Consultants review the results to 
determine whether referral to a Primary Immunodeficiency Center is the next step. The 
Clinical and Laboratory Standards Institute guidelines include detailed information for 
laboratory practice including calibration, quality control, and proficiency testing; [18]. These 
guidelines also address program issues such as short-term follow-up. There is significant 
variability in how individual states conduct notification and tracking to establish or rule out a 
diagnosis. Methods used in California have demonstrated highly efficient means of 
obtaining; secondary testing and determining appropriate disposition.
8. Preterm and Neonatal Intensive Care Infants
Premature infants and those in the neonatal intensive care unit (NICU) are a disproportionate 
source of abnormal TREC results. Kwan, A.; et al. (2013) reported on the first two years of 
SCID NBS in California [19]. Preterm infants with TCL born at 24 to 27 weeks’ gestation 
with the birth weights of 300 to 1200 g had a higher rate; of abnormal TREC results than 
larger, more mature infants. For 6 surviving infants, subsequent lymphocyte profiles 
exhibited an improvement in T-cell numbers over time (Figune 6) [19].
In the same report, proportions of samples from regular nurseries versus neonatal intensive 
care units (NICUs) were described in detail [19]. Of the total 993,724 samples screened, 879 
infants had initial TREC numbers less than the acceptable cutoff, with a predominant 
contribution of 85% from NICUs. A second dried blood spot (DBS) was requested rather 
Dorsey and Puck Page 4
Int J Neonatal Screen. Author manuscript; available in PMC 2019 July 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
than immtdiate flow cytometry fot all infants who lead low TREC numbers, but also low β-
actin control amplification; second DBS tests were also done for low TREC numbers in 
NICU infants. NICU samples accounted for 90% of requests for a second DBS. Only 11% 
of second samples obtained when infants were between 3 and 4 weeks of age were 
persistently abnormal. The 161 infants who underwent flow cytometry) for lymphocyte 
analysis represented 1 in 6200 births, with 66% from NICUs.
9. Early Management and Laboratory Assessment for a New Infant with 
Suspected SCID
Immediate isolation and avoidance of contact with ill persons is advised for infants with 
suspected SCID. Providers should omit live vaccines including rotavirus and advise mothers 
to suspend nursing while evaluating maternal cytomegalovirus (CMV) IgG for evidence of 
prior exposure status. Consultetion with an immunologist is an important next step. Infant 
care includes directed history with family history including; consanguinity, along; with 
careful physical examination focusing on signs of infection, congenital anomalies, rashes 
and respiratory status as part of the early clinical assessment. Confirmation of lymphopenia 
includes repeating measurement op lymphocyte subsets including T-cell CD45RA/RO by 
flow cytometry and also obtaining quantitative serum immunoglobulins. Evaluate 
lymphocyte function via PHA stimulation as part of the work up. At this point, for infants 
meeting SCID criteria, IgG replacement therapy is initiated. A single nucleotide 
polymorphism (SNP) array is obtained for infants with cardiac anomalies or features 
suggestive of DiGeorge or other syndromes. Further testing includes blood chemistries, 
albumin, liver function tests, and total bilirubin. Tests for infection should include PCR or 
antigen (not antibody) for adenovirus, CMV, EBV, HepB, HIV, HSV, and parvovirus B19. 
Limit blood volumes nd do not draw all labs at one to prevent iatrogenic anemia. For 
prophylaxis, initiate fluconazole and acyclovir sequentially over the first 2 weeks; TMP-
SMX after 4 weeks.
10. Special Management Considerations
ADA deficiency SCID occurred in 19% of cases in the California series. Early complications 
include neutropenia which is seen in the majority of infants with ADA SCID and pulmonary 
alveolar proteinosis (PAP), which can lead to respiratory distress and require intubation and 
ventilatory support in severe cases [20]. These conditions generally resolve once ADA 
replacement therapy restores adequate levels of ADA enzyme.
Infants with OS due to hypomorphic mutations in any SCID gene, but recombination-
activating genes RAG1 and RAG2 particularly require immunosuppression while awaiting 
hematopoietic cell transplantation (HCT).
Radiation-sensitive SCID includes deficiencies of Artemis, DNA ligase IV, DNA-dependent 
protein kinase catalytic subunit, Cernunnos-XLF, and nibrin (associated with Nijmegen 
breakage syndrome). Radiation exposure from X-rays and CT scans should be limited in 
these patients except when results influence management.
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Small infants with SCID are susceptible to iatrogenic anemia. Blood draws should be limited 
to smallest possible volume to prevent the need for transfusion which poses risks for 
infection and allosensitization. The unique psychosocial vulnerability of parents of infants 
diagnosed with SCID should be recognized and social work interaction is recommended 
early to identify and support families with high risk of destabilization of family function.
11. Treatment
Hematopoietic cell transplant is the definitive treatment for SCID when there is a human 
leukocyte antigen-matched sibling, the ideal donor. The key to successful treatment 
outcomes is to avoid infection in the infant before transplant [5]. Pai et al., in 2014, reported 
that infants who received transplants before 3.5 months of age had a 5-year survival rate of 
94% as did infants older than 3.5 months but with no history of infection (90%) or whose 
infections had fully resolved with treatment by the time of HCT (82%). [5] In contrast, 
children older than 3.5 months with active infection at the time of HCT and no HLA-
matched sibling had the lowest survival rate (50%). Gene therapy (GT) for correction of 
autologous hematopoietic stem cells through research protocols has been successful for 
children with ADA and X-linked (IL2RG) SCID. Similar GT opportunities for Artemis 
SCID will soon be available.
12. Conclusions
Advances in SCID NBS over the last 9 years have profoundly improved outcomes of 
children born with SCID in the US. Each state institutes different methods of TREC assay 
and follow up and tracking of abnormal results, but detection of typical and leaky SCID by 
TREC screening has been universally successful.
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Figure 1. 
Map of United States showing the implementation of SCID newborn screening.
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Figure 2. 
Identification of T-cell immune defects by means of TREC NBS. Primary immune defects 
can also be diagnosed based on a history of affected family members or clinical features. 
Figure adapted from Dorsey, M.J.; et al. 2017 [15]. *Variable can be < 200 naïve CD4 T 
cells; **Omenn syndrome is a form of leaky SCID with rash; eosinophilia; autoreactive, 
oligoclonal T-cells; and variable CD3 T cell count which can be >1500; ***Some infants 
never leave this group but some move out of this category when other diagnoses are made. 
These infanes need to be followed over time.
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Figure 3. 
Primary immune deficiency treatment consortium SCID diagnosis by screening vs. 
infection, family history. Deta collected from PIDTC 2010–2016 [16].
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Figure 4. 
Distribution of SCID genotypes in the presence of severe combined immunodeficiency 
newborn screening. Data are from a 11 SCID NBS programs in the US with over 3 million 
infants screened.
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Figure 5. 
California SCID NBS algorithm. Cutoff values for TREC and β-actin gene copies/μL of 
blood are determined using the PerkinElmer Enlite Kit. Samples with more than 18 TRECs/
μL on initial testing are considered normal. Samples with 18 TRECs/μL or fewer have repeat 
TREC and β-actin testing of these, samples fewer than 3 TRECs are urgent positive, with 
lymphocyte subset determination by flow cytometry ordered immediately. Samples with 4–
18 TRECs/μL are categorized rs positive if β-actin values aro above 35 copies, and 
lymphocyte subset determinatian by flow cytometry is ordered. Samples with insufficient 
control actin DNA amplification are designated DAF, DNA amplification failupe. These 
infants require o repeat heel-stick sample, or ii it is already a second sample, lymphocyte 
subset determination. NICU, neonatal intensive care unit. Incomplete, DBS result with both 
low TRECs and low β-actin copy number. CBC, complete blood count.
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Figure 6. 
Preterm low birthweight infants with low TRECs and T lymphopenia. Birth weights (BW) 
are indicated. Subsequent T-cell concentrations were greater than 1500 cells/μL (dotted 
line); the threshold was set by using the California Newborn Screening Program. Figure 
adapted from Kwan, A. et al., 2013 [19].
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Table 1.
Frequency of non-SCID conditions identified by SCID NBS in California.
Conditions %
Multisyndromes with variable T-cell deficiency
DiGeorge/chromosome 22q11.2 deletion 57
Trisomy 21 15
Ataxia telangiectasia 3
CHARGE syndrome 2
Secondary T lymphopenia
Congenital cardiac anomalies 25
Other congenital anomalies 38
Vascular leakage, third spacing, hydrops 13
Neonatal leukemia 3
Maternal immunosuppressive medications 3–5
Extreme preterm birth (T cells become normal over time)
Idiopathic T lymphopenia (no gene defect, few naïve cells, impaired T cell function)
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